The U.S. Supreme Court on Thursday preserved nationwide mail access to the abortion pill mifepristone, putting on hold a lower-court ruling that would have required patients to see a doctor in person and blocked prescriptions via telehealth.
"What is at stake is the perpetration of a scheme to undermine our decision in Dobbs v. Jackson Women’s Health Organization," Justice Samuel Alito wrote in a dissent, joined by Justice Clarence Thomas, arguing the availability of the pill by mail thwarts state-level abortion bans.
The decision impacts a method that accounted for 65% of the 1.1 million clinician-provided abortions in the U.S. in 2023, according to the Guttmacher Institute. The ruling is a temporary victory for drugmakers Danco Laboratories and GenBioPro, which had warned that the Fifth Circuit's May 1 decision would cause "chaos" for patients and providers who have come to rely on virtual appointments.
While maintaining the status quo, the court’s unsigned order does not resolve the core legal conflict. The case now returns to the lower courts, ensuring continued regulatory uncertainty for the pharmaceutical and burgeoning telehealth industries and setting the stage for a future battle over the FDA’s authority and the enforcement of the long-dormant Comstock Act.
The legal fight stems from a lawsuit by Louisiana, which argues that the FDA’s 2023 decision to permanently allow mifepristone to be prescribed remotely and mailed to patients undermines its state-level abortion ban. The state claimed it suffered financial injury, citing over $17,000 spent investigating out-of-state providers and at least $92,000 in Medicaid costs for two women who allegedly suffered complications.
In his dissent, Justice Thomas argued the drug manufacturers were not entitled to a stay, referencing the 1873 Comstock Act that criminalizes the mailing of abortion-related drugs. "They are not entitled to a stay of an adverse court order based on lost profits from their criminal enterprise," Thomas wrote. This marks a significant reference to a law that anti-abortion advocates have urged the government to enforce.
For providers, the ruling averts an immediate logistical crisis. "This isn’t a matter of convenience — for patients living hundreds of miles from the nearest clinic, it’s the difference between getting an abortion or not," said Nancy Northup, president of the Center for Reproductive Rights.
This is the second time in two years the Supreme Court has intervened to protect access to mifepristone, which was first approved by the FDA in 2000. In 2024, the court unanimously rejected a similar challenge from a group of anti-abortion doctors, ruling they lacked the legal standing to sue. The current case, brought by a state, presents a more direct challenge to the FDA's regulatory power.
The case now proceeds on the merits in the Fifth Circuit, with the potential to return to the Supreme Court for a final decision on whether the FDA's rules are valid. The outcome will have major implications for the future of abortion access and the regulatory authority of federal agencies over state laws.
This article is for informational purposes only and does not constitute investment advice.
